MHAA4549A is a human IgG1 monoclonal antibody developed to treat
influenza A infection. It targets a conserved epitope on the
hemagglutinin stalk of the virus, neutralizing a wide range of
influenza A strains. It has been tested in both healthy volunteers
and hospitalized patients and was shown to be safe, with
predictable pharmacokinetics similar to other IgG1 antibodies.
References
Deng, R., Lee, A.P., Maia, M. et al. Pharmacokinetics of
MHAA4549A, an Anti-Influenza A Monoclonal Antibody, in Healthy
Subjects Challenged with Influenza A Virus in a Phase IIa
Randomized Trial. Clin Pharmacokinet 57, 367–377 (2018).
https://doi.org/10.1007/s40262-017-0564-y
Generated at 2026-04-15T18:18:36Z by OpenModelicaOpenModelica 1.26.3 using
GenerateDoc.mos
.Pharmacolibrary.Drugs.Z_Unclassified.J06B_ProbableImmunoglobulins.MHAA459A.MHAA459A_2C